17.02
0.59%
+0.10
After Hours:
17.02
Quanterix Corp stock is currently priced at $17.02, with a 24-hour trading volume of 364.66K.
It has seen a +0.59% increased in the last 24 hours and a -22.50% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $16.78 pivot point. If it approaches the $17.35 resistance level, significant changes may occur.
Previous Close:
$16.92
Open:
$17.19
24h Volume:
364.66K
Market Cap:
$650.97M
Revenue:
$121.14M
Net Income/Loss:
$-32.33M
P/E Ratio:
-9.6158
EPS:
-1.77
Net Cash Flow:
$-22.69M
1W Performance:
+9.38%
1M Performance:
-22.50%
6M Performance:
-25.74%
1Y Performance:
+3.78%
Quanterix Corp Stock (QTRX) Company Profile
Name
Quanterix Corp
Sector
Industry
Phone
617-301-9400
Address
113 Hartwell Avenue, Lexington, MA
Quanterix Corp Stock (QTRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-08-23 | Upgrade | SVB Securities | Market Perform → Outperform |
May-23-23 | Upgrade | Goldman | Neutral → Buy |
Aug-15-22 | Downgrade | Canaccord Genuity | Buy → Hold |
Aug-09-22 | Downgrade | Cowen | Outperform → Market Perform |
Aug-09-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Mar-02-22 | Upgrade | Goldman | Sell → Neutral |
Oct-15-21 | Resumed | Cowen | Outperform |
Jun-04-21 | Initiated | Goldman | Sell |
View All
Quanterix Corp Stock (QTRX) Latest News
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
Zacks Investment Research
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
Zacks Investment Research
Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy
Zacks Investment Research
Does Quanterix Corporation (QTRX) Have the Potential to Rally 33.74% as Wall Street Analysts Expect?
Zacks Investment Research
Wall Street Analysts See a 54.88% Upside in Quanterix Corporation (QTRX): Can the Stock Really Move This High?
Zacks Investment Research
Quanterix Corp Stock (QTRX) Financials Data
Quanterix Corp (QTRX) Revenue 2024
QTRX reported a revenue (TTM) of $121.14 million for the quarter ending December 31, 2023, a +15.42% rise year-over-year.
Quanterix Corp (QTRX) Net Income 2024
QTRX net income (TTM) was -$32.33 million for the quarter ending December 31, 2023, a +66.56% increase year-over-year.
Quanterix Corp (QTRX) Cash Flow 2024
QTRX recorded a free cash flow (TTM) of -$22.69 million for the quarter ending December 31, 2023, a +62.18% increase year-over-year.
Quanterix Corp (QTRX) Earnings per Share 2024
QTRX earnings per share (TTM) was -$0.86 for the quarter ending December 31, 2023, a +67.05% growth year-over-year.
About Quanterix Corp
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. Quanterix Corporation has collaboration agreements with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122; and OncoGenesis Corp to develop a protein biomarker diagnostic test for cervical health using its Simoa Planar Technology. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.
Cap:
|
Volume (24h):